Document is current
Any future updates will be listed below
-
Authors
Edmonds, KeHuan K. https://orcid.org/0000-0002-7317-2669
Wilkinson, Max E.
Strebinger, Daniel https://orcid.org/0000-0001-8732-6414
Chen, Hongyu https://orcid.org/0000-0002-9496-8586
Lash, Blake https://orcid.org/0000-0003-2445-7948
Schaefer, Clarissa C. https://orcid.org/0009-0005-3701-913X
Zhu, Shiyou
Liu, Dangliang https://orcid.org/0000-0001-6598-8871
Zilberzwige-Tal, Shai
Ladha, Alim
Walsh, Michelle L.
Frangieh, Chris J.
Vaz Reay, Nicholas A.
Macrae, Rhiannon K. https://orcid.org/0000-0002-7850-9056
Wang, Xiao
Zhang, Feng https://orcid.org/0000-0003-0178-7995
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
German Academic Scholarship Foundation
Research Science Institute
- License Information
-
More Information
Article History
Received: 13 September 2024
Accepted: 16 June 2025
First Online: 2 July 2025
Competing interests
: F.Z. is a scientific advisor and cofounder of Beam Therapeutics, Pairwise Plants, Arbor Biotechnologies, Aera Therapeutics, and Moonwalk Biosciences. F.Z. is a scientific advisor for Octant. X.W., H.C., and D.L. have submitted a patent application to the U.S. Patent and Trademark Office related to 5′ chemically modified RNAs (International Publication No. WO 2025/04308; PCT converted). X.W. is a consultant, equity holder and scientific cofounder of Stellaromics and Convergence Bio. The remaining authors declare no competing interests.
